John Theurer Cancer Center | Strategic Alliance Partners

Finding new ways of manipulating the body's own defenses to better combat various hematologic malignancies is yielding some interesting results and could represent a very promising new field of care for patients dealing with these disorders.

While the anti-T-cell-checkpoint approach is far from perfect, the demonstrated ability for humanity to overcome evolutionary design and break tumor cell tolerance to turn the tide against cancer is nothing less than inspiring.

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, discusses the approval of the immunomodulatory agent lenalidomide (Revlimid).

On Sunday, December 9, 2012, the Plenary Session at the 54th American Society of Hematology Annual Meeting featured several noteworthy abstracts.

It has always been our job as cancer care physicians to guide the patient, even when our guidance is not what one would like to hear.

We have come a long way from the microscope of Galileo, but questions remain in actual practice about how close we need to get to help our patients.

The real question is how will we best use our continually evolving armamentarium of treatments to deliver the best outcomes while optimizing the cost of care for our patients.

Over the past decade, there has been an explosion of knowledge regarding the fundamental drivers of the malignant phenotype.

New data from a study sponsored by the National Institutes of Health appear to have proven that there is an inexpensive and relatively simple approach to reducing the incidence of most cancers that afflict men: Take a multivitamin daily.

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

Robin McConnell, from John Theurer Cancer Center, Discusses Nutrition in Cancer Care

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

The John Theurer Cancer Center (JTCC), at Hackensack University Medical Center in New Jersey, is one of the largest cancer facilities in the US.

Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL

David S. Siegel, MD, PhD, chief, Multiple Myeloma at the John Theurer Cancer Center (JTCC), discusses the new JTCC stand alone cancer center.